2019年糖尿病研究进展年终盘点

2020-01-12 MedSci MedSci原创

 2019年美国糖尿病协会科学会议于2019年6月7-11日在美国旧金山举行,美国糖尿病年会(ADA年会)是世界上最大、最重要的糖尿病会议,每年都会吸引近18,000名来自世界各地的参与者,其中包括13,000多名医护工作人员等。5天的会议,为与会者提供与领先的糖尿病专家交流互动、分享看法,为研究人员和医疗保健专业人士提供了解当前关于糖尿病研究、治疗和护理的重大进展,以及访问超过

《2020年ADA糖尿病医学诊疗标准》公布 “是否应将成年人缓慢进展的自身免疫性糖尿病称为成人隐匿型自身免疫性糖尿病”的争论已有定论 ➤ 增加了一项新的关于超重或肥胖和/或伴有一个或多个额外糖尿病危险因素并计划妊娠的女性糖尿病前期和/或2型糖尿病的检测推荐(2.8)。 ➤ 在“囊性纤维化相关糖尿病”(CFRD)部分增加了使用糖化血红蛋白(A1C)检测CFRD的注意事项。 ➤ 新增“胰腺性糖尿病或外分泌腺胰疾病背景下的糖尿病”章节,描述了该类型的糖尿病及其多种病因。 ➤ 修订了“妊娠期糖尿病”(GDM)部分,筛查与诊断GDM的两步法不再包括国家糖尿病数据组标准。ADA/EASD最新共识 对于伴有致动脉粥样硬化性心血管疾病(如伴有心肌梗死、缺血性卒中、有ECG改变的不稳定心绞痛、影像学检查或负荷试验显示的心肌缺血、冠脉/颈动脉/外周动脉血运重建)的T2DM患者,MACE是最严重的威胁。这些患者应用GLP-1受体激动剂实现MACE获益的证据最强。 基于REWIND研究最新结果推荐,无心血管疾病但存在相关高危因素(尤其是年龄≥55岁伴有冠脉/颈动脉/下肢

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-13 yjs木玉

    好好好好好好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-13 Dr Z

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-13 misszhang

    谢谢MedSci提供最新的资讯

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1381240, encodeId=5be1138124043, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514947, encodeId=14e4151494ebb, content=<a href='/topic/show?id=6209489541d' target=_blank style='color:#2F92EE;'>#年终盘点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48954, encryptionId=6209489541d, topicName=年终盘点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a0d10697935, createdName=ms9833124466084992, createdTime=Tue Jan 14 14:49:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378099, encodeId=e3903e80993b, content=好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Mon Jan 13 08:14:08 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378095, encodeId=bd2a3e809507, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Jan 13 07:15:57 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042924, encodeId=316c104292420, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Jan 13 02:49:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378088, encodeId=d3423e808805, content=***, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Mon Jan 13 00:06:05 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-13 yangchou

    ***

    0

相关资讯

糖皮质激素引起的糖尿病,值得所有临床医生关注!

糖皮质激素因其多种作用,被广泛用于临床多种疾病的短期或长期治疗。但它是把双刃剑,在发挥作用的同时,也不可避免地会引起一些副作用,血糖异常便是其中常见的情况之一。

BMJ:健康生活方式与慢病风险

研究发现,坚持健康的生活方式可显著降低多种慢性疾病风险

Lancet Diabetes Endo:杜拉鲁肽可降低II型糖尿病患者缺血性中风风险

研究发现,长期使用杜拉鲁肽可减少II型糖尿病患者临床相关的缺血性中风风险,但不影响中风的严重程度

研究太极拳治糖尿病,福建中医药大学副校长获880万经费

记者注意到,福建中医药大学官网12月27日发布消息《我校获批国家重点研发计划重点专项》透露:近日,我校陶静副校长主持的“太极拳对2型糖尿病及脑卒中功能康复效果的临床研究”获国家重点研发计划“中医药现代化研究”重点专项2019年度项目立项,资助经费880万元,实现我校在国家重点研发计划中“零”的突破。学校官网介绍:陶静,女,汉族,江苏淮安人,1977年2月出生,中共党员,研究生学历,医学博士,教授,

中国糖尿病患者激增,警惕肥胖“助攻”

中国糖尿病患病率居高不下,日益普遍的肥胖现象“贡献”不小。昨天,《柳叶刀-糖尿病与内分泌学》在线发表了一项来自中国多中心、大样本的前瞻性队列研究,系统分析了胰岛素抵抗、β细胞功能障碍及两者的交互作用对2型糖尿病发生风险的作用,揭示了肥胖对中国糖尿病发病的重要影响。中国糖尿病患病率急剧增长,以往的观点认为,β细胞功能障碍是中国人2型糖尿病的主要发病机制。但专家发现,β细胞功能障碍不足以解释糖尿病患病

预防糖尿病,喝咖啡有讲究:喝过滤咖啡才有用!

既往研究提示,喝咖啡可能有助于预防2型糖尿病,但咖啡的制作方法不同时,效果可能会截然不同。一项来自瑞典的病例对照研究表明,与从来不喝咖啡的人相比,经常喝过滤咖啡的人中2型糖尿病10年发生风险明显降低,而经常喝煮沸的咖啡并没有这种效果。研究者发现,校正多个潜在混淆因素后,与平均每天喝咖啡不足1杯(1杯=150 ml)的人相比,每天喝2~3杯过滤咖啡的成年人10年内发生2型糖尿病的风险降低58%。但是